Search results for "LIPIDS"

showing 10 items of 2228 documents

Effects of oral contraceptives on metabolic profile in women with polycystic ovary syndrome: A meta-analysis comparing products containing cyproteron…

2017

Abstract Background Although oral contraceptives (OCs) are the most common treatment in women with polycystic ovary syndrome (PCOS), their effects and safety on the metabolic profiles of these patients are relatively unknown. In this meta-analysis the effects of the different durations (from 3 months to 1 year) of OC treatment using cyproterone acetate (CA) or third generation progestins on metabolic profile of patients with PCOS were assessed. Materials and methods PubMed, Scopus, Google Scholar and ScienceDirect databases (2001–2015) were searched to identify clinical trials investigating the effects of OC containing CA or third generation progestins on metabolic profiles of women with PC…

Blood Glucosemedicine.medical_specialtyTime Factorsmedicine.drug_classEndocrinology Diabetes and MetabolismBlood lipidsBlood Pressure030209 endocrinology & metabolism03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInsulin resistanceDesogestrelInternal medicinemedicineHumansInsulinCyproterone AcetateClinical Trials as Topic030219 obstetrics & reproductive medicinebusiness.industryBody WeightCyproterone acetateDrospirenoneLipid Metabolismmedicine.diseasePolycystic ovaryEndocrinologychemistryMetabolomeFemaleProgestinsbusinessProgestinBody mass indexContraceptives OralPolycystic Ovary Syndromemedicine.drugMetabolism
researchProduct

Metabolic effect of berberine-silymarin association: A meta-analysis of randomized, double-blind, placebo-controlled clinical trials.

2019

The aim of this study is to assess the impact of a combination of berberine and silymarin on serum lipids and fasting plasma glucose (FPG) through a systematic review of literature and meta-analysis of the available randomized, double-blind, placebo-controlled clinical trials (RCTs). A systematic literature search in SCOPUS, PubMed-Medline, ISI Web of Science, and Google Scholar databases was conducted up to October 2, 2018, in order to identify RCTs assessing changes in plasma concentrations of total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and FPG during treatment with berberine and silymarin in combina…

Blood Glucosemedicine.medical_specialtysilymarinReviewsBlood lipidsberberine; cholesterol; fasting plasma glucose; meta-analysis; nutraceutical; silymarin; Berberine; Blood Glucose; Double-Blind Method; Fasting; Humans; Lipids; Randomized Controlled Trials as Topic; SilymarinReviewPlaceboGastroenterologymeta-analysiDouble blind03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBerberineDouble-Blind MethodInternal medicineberberineMedicineHumansfasting plasma glucoseRandomized Controlled Trials as TopicPharmacology0303 health sciencesbusiness.industryCholesterolData synthesis030302 biochemistry & molecular biologycholesterolFastingLipidsClinical trialmeta-analysischemistrymeta‐analysis030220 oncology & carcinogenesisMetabolic effectsMeta-analysisnutraceuticalCardiology and Cardiovascular Medicinebusiness
researchProduct

Effects Of Combined Strength And Endurance Training On Physical Performance And Biomarkers Of Healthy Young Women

2018

Kyröläinen, H, Hackney, AC, Salminen, R, Repola, J, Häkkinen, K, and Haimi, J. Effects of combined strength and endurance training on physical performance and biomarkers of healthy young women. J Strength Cond Res 32(6): 1554– 1561, 2018—Cardiovascular fitness has decreased and obesity has increased in young adults worldwide during the last 10 years. Therefore, there is an urgent need to find out optimal exercise training programs for improving physical performance and health outcomes, especially among sedentary women. Subjects were 25- to 30-year-old women with a very low physical activity, and 65% of them were overweight (body mass index . 25). They performed endurance and strength traini…

Blood GlucosenaisetHydrocortisonekestävyysharjoitteluIsometric exerciseOverweightliikuntaBody Mass Indexsedentary womenHemoglobinsphysical training0302 clinical medicineSex Hormone-Binding GlobulinTestosteroneOrthopedics and Sports Medicine030212 general & internal medicineta315EstradiolVO2 maxGeneral MedicineLipoproteins LDLfyysinen kuntoCholesterolFemalevoimaharjoittelumedicine.symptomLipoproteins HDLAdultmedicine.medical_specialtyStrength trainingPhysical Therapy Sports Therapy and Rehabilitation03 medical and health sciencesOxygen ConsumptionEndurance trainingmedicineHumansMuscle StrengthExercise physiologyMuscle SkeletalExerciseTriglycerideskehonkoostumusnuoret aikuisetbody compositionhormonesblood lipidsbusiness.industryResistance Training030229 sport sciencesmedicine.diseaseObesityhormonitBicyclingPhysical Endurancephysical fitnessPhysical therapySedentary BehaviorbusinessBody mass indexBiomarkers
researchProduct

Comparative lipidomics and proteomics analysis of platelet lipid rafts using different detergents

2016

Lipid rafts play a pivotal role in physiological functions of platelets. Their isolation using nonionic mild detergents is considered as the gold standard method, but there is no consensual detergent for lipid raft studies. We aimed to investigate which detergent is the most suitable for lipid raft isolation from platelet membrane, based on lipidomics and proteomics analysis. Platelets were obtained from healthy donors. Twelve sucrose fractions were extracted by three different detergents, namely Brij 35, Lubrol WX, and Triton X100, at 0.05% and 1%. After lipidomics analysis and determination of fractions enriched in cholesterol (Ch) and sphingomyelin (SM), proteomics analysis was performed…

Blood Platelets0301 basic medicineProteome[SDV]Life Sciences [q-bio]Detergents030204 cardiovascular system & hematologyProteomics03 medical and health scienceschemistry.chemical_compoundMembrane Microdomains0302 clinical medicineproteomicsLipidomicsCentrifugation Density GradientHumansLipid raftlipid rafts[ SDV ] Life Sciences [q-bio]ChemistryCholesterolMembrane ProteinsHematologyGeneral MedicineLipids6. Clean water030104 developmental biologyMembraneBiochemistryMembrane proteinProteomeplateletslipidomicslipids (amino acids peptides and proteins)Sphingomyelin
researchProduct

Impact of ticagrelor on P2Y1 and P2Y12 localization and on cholesterol levels in platelet plasma membrane

2017

Ticagrelor is an antiplatelet agent that inhibits platelet activation via P2Y12 antagonism. There are several studies showing that P2Y12 needs lipid rafts to be activated, but there are few data about how ticagrelor impacts lipid raft organization. Therefore, we aimed to investigate how ticagrelor could impact the distribution of cholesterol and consequently alter the organization of lipid rafts on platelet plasma membranes. We identified cholesterol-enriched raft fractions in platelet membranes by quantification of their cholesterol levels. Modifications in cholesterol and protein profiles (Flotillin 1, Flotillin 2, CD36, P2Y1, and P2Y12) were studied in platelets stimulated by ADP, treate…

Blood Platelets0301 basic medicineTicagrelorAdenosineCD36030204 cardiovascular system & hematologyPharmacologyReceptors Purinergic P2Y103 medical and health scienceschemistry.chemical_compoundMembrane Microdomains0302 clinical medicineP2Y12medicineHumansPlateletPlatelet activationLipid raftbiologyChemistryCholesterolCell MembraneHematologyGeneral MedicineReceptors Purinergic P2Y12Cholesterol030104 developmental biologyMembraneBiochemistryPurinergic P2Y Receptor Antagonistsbiology.proteinlipids (amino acids peptides and proteins)Ticagrelormedicine.drugPlatelets
researchProduct

Vitamin C blocks inflammatory platelet-activating factor mimetics created by cigarette smoking.

1997

Cigarette smoking within minutes induces leukocyte adhesion to the vascular wall and formation of intravascular leukocyte-platelet aggregates. We find this is inhibited by platelet-activating factor (PAF) receptor antagonists, and correlates with the accumulation of PAF-like mediators in the blood of cigarette smoke-exposed hamsters. These mediators were PAF-like lipids, formed by nonenzymatic oxidative modification of existing phospholipids, that were distinct from biosynthetic PAF. These PAF-like lipids induced isolated human monocytes and platelets to aggregate, which greatly increased their secretion of IL-8 and macrophage inflammatory protein-1alpha. Both events were blocked by a PAF r…

Blood PlateletsChemokineAntioxidantTime FactorsPlatelet Aggregationmedicine.drug_classNeutrophilsmedicine.medical_treatmentPhospholipidReceptors Cell SurfaceAscorbic AcidPlatelet Membrane GlycoproteinsPharmacologyAntioxidantsMonocytesReceptors G-Protein-Coupledchemistry.chemical_compoundReference ValuesCricetinaemedicineCell AdhesionAnimalsHumansPlateletPlatelet Activating FactorReceptorChemokine CCL4Cell AggregationLeukocyte aggregationbiologyPlatelet-activating factorChemistryInterleukin-8SmokingGeneral MedicineAzepinesMacrophage Inflammatory ProteinsTriazolesReceptor antagonistBiochemistrybiology.proteinlipids (amino acids peptides and proteins)Platelet Aggregation InhibitorsResearch Article
researchProduct

Anti-inflammatory and analgesic activity of a novel inhibitor of microsomal prostaglandin E synthase-1 expression

2009

Abstract In a previous study, we reported a new γ-hydroxybutenolide derivative, 4-benzo[ b ]thiophen-2-yl-3-bromo-5-hydroxy-5 H -furan-2-one (BTH), as inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1) expression in lypopolysaccharide (LPS) stimulated RAW 264.7 and TPH-1 cells, without affecting cyclooxygenase-2 (COX-2). In this study, we evaluated the in vivo effect of BTH on some acute and chronic inflammatory animal models in relation to its inhibitory profile on mPGES-1 expression. In the zymosan-induced mouse air pouch model, BTH produced a dose-dependent inhibition of prostaglandin E 2 (PGE 2 ) production and mPGES-1 protein expression in pouch exudates without any effect on…

Blood PlateletsMaleNeutrophilsmedicine.drug_classmedicine.medical_treatmentAnti-Inflammatory AgentsProstaglandinInflammationThiophenesAcetatesPharmacologyProstaglandin E synthaseLeukotriene B4Gene Expression Regulation EnzymologicAnti-inflammatoryMicechemistry.chemical_compound4-ButyrolactoneIn vivomedicineAnimalsHumansProstaglandin-E SynthasesInflammationPharmacologyAnalgesicsBehavior AnimalbiologyArthritis ExperimentalIntramolecular OxidoreductasesThromboxane B2BiochemistrychemistryHyperalgesiaChronic DiseaseHyperalgesiabiology.proteinCattlelipids (amino acids peptides and proteins)Arachidonic acidmedicine.symptomProstaglandin E
researchProduct

Membrane fluidity, membrane lipid pattern, and cytosolic Ca2+ content in platelets from a group of type II diabetic patients with macrovascular compl…

1995

OBJECTIVE To evaluate platelet membrane fluidity and some platelet metabolic parameters in type II diabetic patients with macrovascular complications. RESEARCH DESIGN AND METHODS In a group of 21 type II diabetic patients with macrovascular complications, we evaluated platelet membrane fluidity [marking intact resting platelets with the fluorescent probe 1,4-(trimethylamino)-phenyl-4-phenylhexatriene (TMA-DPH)], platelet membrane lipid pattern (cholesterol :phospholipid [C:PL] ratio and individual phospholipids), and platelet cytosolic Ca2+ content (marking intact resting platelets with the fluorescent probe Fura 2AM). RESULTS Platelet membrane fluidity is decreased in type II diabetic pat…

Blood PlateletsMalemedicine.medical_specialtyMembrane FluidityEndocrinology Diabetes and MetabolismPhospholipidchemistry.chemical_elementCalciumchemistry.chemical_compoundMembrane LipidsCytosolInternal medicineDiabetes mellitusInternal MedicineMembrane fluiditymedicineHumansPlateletAgedAdvanced and Specialized NursingCholesterolbusiness.industryPhosphatidylserineMiddle Agedmedicine.diseaseCytosolEndocrinologySpectrometry FluorescencechemistryDiabetes Mellitus Type 2CalciumFemalebusinessDiabetic Angiopathies
researchProduct

Reciprocal regulation of human platelet function by endogenous prostanoids and through multiple prostanoid receptors

2014

Platelets are permanently exposed to a variety of prostanoids formed by blood cells or the vessel wall. The two major prostanoids, prostacyclin and thromboxane act through well established pathways mediated by their respective G-protein coupled receptors inhibiting or promoting platelet aggregation accordingly. Yet the role of other prostanoids and prostanoid receptors for platelet function regulation has not been thoroughly investigated. We aimed at a comprehensive analysis of prostanoid effects on platelets, the receptors and pathways involved and functional consequences. We analyzed cAMP formation and phosphorylation of proteins pivotal to platelet function as well as functional platelet…

Blood PlateletsSerotoninmedicine.medical_specialtyPlatelet AggregationProstaglandin E2 receptorReceptors ProstaglandinProstaglandinProstacyclinchemistry.chemical_compoundAdenosine TriphosphateP2Y12Internal medicineCyclic AMPmedicineHumansPlateletPlatelet activationReceptorMitogen-Activated Protein Kinase KinasesPharmacologyChemistryMicrofilament Proteinsrap1 GTP-Binding ProteinsProstanoidrespiratory systemPhosphoproteinsCell biologyAdenosine DiphosphateP-SelectinEndocrinologyProstaglandinscardiovascular systemCalciumlipids (amino acids peptides and proteins)Cell Adhesion Moleculesmedicine.drugEuropean Journal of Pharmacology
researchProduct

Coronary artery disease: Risk stratification and patient selection for more aggressive secondary prevention.

2017

In patients with stable coronary artery disease, clinical outcomes are predominantly characterized by the consequences of atherosclerosis on the myocardium, but also by complications of atherosclerosis, notably recurrent acute coronary syndrome or stroke. Secondary prevention therapy is therefore key in this patient population. Intensification of secondary prevention therapy is possible, at the price of a therapeutic risk or a high cost, therefore justifying careful selection of patients with a high residual risk and low therapeutic risk. Two lines of therapy can be intensified, independently of each other, namely anti-thrombotics and lipid-lowering agents. Intensification of anti-thromboti…

Blood Plateletsmedicine.medical_specialtyAcute coronary syndromeStatinEpidemiologymedicine.drug_classCoronary Artery Disease030204 cardiovascular system & hematologyCoronary artery disease03 medical and health sciences0302 clinical medicineEzetimibeFibrinolytic AgentsRecurrenceRisk FactorsInternal medicineDiabetes mellitusmedicineSecondary PreventionHumans030212 general & internal medicineMyocardial infarctionStrokeBlood CoagulationDyslipidemiasHypolipidemic Agentsbusiness.industryPatient Selectionmedicine.diseaseLipidsResidual riskTreatment OutcomeDisease ProgressionCardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugEuropean journal of preventive cardiology
researchProduct